Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y5B8

UPID:
NDK7_HUMAN

ALTERNATIVE NAMES:
nm23-H7

ALTERNATIVE UPACC:
Q9Y5B8; A8K3T6; A8MY09; B3KSW9; Q5TGZ4

BACKGROUND:
The enzyme Nucleoside diphosphate kinase 7, also known as nm23-H7, is crucial for the generation of nucleoside triphosphates beyond ATP, utilizing a unique ping-pong mechanism. This process is vital for cellular energy balance. Moreover, its role as a Microtubule inner protein in cilia axoneme underscores its importance in the structural integrity and function of motile cilia, which are key to cellular movement and fluid dynamics in various physiological processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Nucleoside diphosphate kinase 7 offers a promising avenue for the development of novel therapeutic approaches, especially for diseases affecting cellular energy processes and motility.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.